Check it out: other trials have interim anslysisanslysis even when the primary endpoint is PFS. It looks like they don't want people to see the results until they have to release them. In other words keep the illusion of potential success going as long as possible.
May 30, 2015 - At a pre-planned interim analysis earlier this year, the addition of ibrutinib to BR was shown to significantly improve progression-free survival (PFS; the primary endpoint)
Feurstein Ratain rule has a perfect track record. Meaning unless this stock more than doubles by 4 months before release of phase III results, there is a essentially zero chance of approval.
Does anyone know when phase 3 results are due? Basically, the stock needs to more than double at least 4 months in advance of that date. Otherwise, the drug is virtually guaranteed to fail.
Fuerstein Ratain rule statesstates that four months before phase 3 results are announced, a market cap under $300 million forecasts phase III study failure. If the market cap is between $300 million and a billion then the success rate is 59%. These rules are at least 5 years old so the numbers should be adjusted upwards for inflation. CYTR's current market cap is only $150 million, with more dilution and price depreciation likely on the way!
Unless they do a reverse split. I guess the offering was a smart move after all. Got to pay for management's obscene salaries somehow.
Kriegsman has already made countless millions. I doubt it matters to him whether the stock gets delisted at this point.
Come on, that's only 30+ years. These things take time. Give them a few more decades.aybe Kriegsman will transform the company into a toilet paper products company if the drug thing doesn't work.
At the rate this is dropping it will be trading on the pink sheets for a penny or two in 3-4 months.